{"gene":"EFEMP1","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1999,"finding":"A single non-conservative missense mutation (Arg345Trp) in EFEMP1 was identified as the cause of both Malattia Leventinese and Doyne honeycomb retinal dystrophy, establishing EFEMP1 as the disease gene for these inherited macular degenerations characterized by drusen accumulation beneath the RPE.","method":"Positional cloning combined with candidate gene sequencing in affected families; mutation absent in 477 controls and 494 AMD patients","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — positional cloning with candidate gene sequencing, replicated across multiple families, mutation-phenotype co-segregation established","pmids":["10369267"],"is_preprint":false},{"year":2002,"finding":"Wild-type EFEMP1 is a secreted protein, whereas the R345W mutant is misfolded, secreted inefficiently, and retained intracellularly; in ML eyes mutant EFEMP1 accumulates within RPE cells and between RPE and drusen, suggesting aberrant intracellular retention drives drusen formation.","method":"Cell transfection secretion assays, immunolocalization in human ML and AMD eye sections, Western blot","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (secretion assay, immunohistochemistry in human tissue), consistent findings across ML and AMD specimens","pmids":["12242346"],"is_preprint":false},{"year":2004,"finding":"TIMP-3 (tissue inhibitor of metalloproteinases-3) was identified as a binding partner of EFEMP1 in the subretinal space; the COOH-terminal end of TIMP-3 mediates the interaction, linking two macular degeneration disease proteins.","method":"In vivo subretinal binding partner screen, Co-immunoprecipitation/pulldown, expression overlap analysis in human ML and AMD eye sections","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding confirmed in vivo and by co-localization in human tissue; domain mapping of TIMP-3 C-terminus involvement","pmids":["15123717"],"is_preprint":false},{"year":2007,"finding":"The R345W mutation in EFEMP1 is pathogenic: Efemp1-R345W knockin mice develop sub-RPE basal deposits containing Efemp1 and Timp3, and show evidence of complement activation in RPE/Bruch's membrane, recapitulating AMD-like pathology.","method":"Efemp1-R345W knockin mouse generation, histopathology, immunofluorescence for Efemp1 and Timp3 in deposits, complement activation assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockin model with histopathological, proteomic, and complement activation readouts; replicated by second concurrent knockin study (PMID:17664227)","pmids":["17666404","17664227"],"is_preprint":false},{"year":2007,"finding":"Efemp1 R345W knockin mice develop small isolated sub-RPE deposits as early as 4 months, progressing to continuous sheets with membranous debris, RPE vacuolation, choroidal atrophy, and Bruch's membrane thickening; fibulin-3 accumulates in sub-RPE deposits.","method":"Knock-in mouse model histopathology, electron microscopy, immunofluorescence for fibulin-3 in deposits","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knock-in model with detailed longitudinal histopathological characterization, replicated in concurrent knockin study (PMID:17666404)","pmids":["17664227"],"is_preprint":false},{"year":2009,"finding":"EFEMP1 binds the EGF receptor (EGFR) competitively relative to EGF, and treatment of pancreatic carcinoma cells with purified EFEMP1 activates EGFR autophosphorylation at Tyr-992 and Tyr-1068, followed by downstream phosphorylation of Akt (Thr-308) and p44/p42 MAPK (Thr-202/Tyr-204); these effects are blocked by the EGFR kinase inhibitor PD 153035.","method":"Competitive binding assay (EFEMP1 vs EGF for EGFR), phospho-Western blot for EGFR, Akt, and MAPK phosphorylation sites, kinase inhibitor treatment","journal":"Biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct binding competition assay plus multi-site phosphorylation mapping with site-specific antibodies and pharmacological inhibition in a single study","pmids":["19804359"],"is_preprint":false},{"year":2011,"finding":"Secretion deficiency of R345W EFEMP1 is caused, in part, by reduced native disulfide bonding in the sixth EGF-like domain harboring position 345; aromatic residue substitutions (Trp, Tyr, Phe) at position 345 cause significant secretion deficiencies; mutant secretion and proper disulfide formation are enhanced by reduced growth temperature or translational attenuation.","method":"Cell-based Gaussia luciferase secretion assay, panel of position-345 mutants, disulfide bond analysis, pharmacological proteostasis manipulation","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis series, biochemical disulfide analysis, and functional rescue experiments in a single rigorous study","pmids":["22031286"],"is_preprint":false},{"year":2013,"finding":"Genetic ablation of complement component C3 (but not C5) in Efemp1-R345W knockin mice inhibits formation of sub-RPE basal deposits; proteomic analysis of Bruch's membrane showed basal deposits contain normal ECM components in abnormal amounts and significant increases in complement proteins, demonstrating a critical role for complement (via C3) in basal deposit formation.","method":"Double-mutant mouse genetics (Efemp1(R345W/R345W):C3(-/-)), proteomics of Bruch's membrane/choroid, histopathology","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double-mutant mice plus proteomic validation, replicated with C5 study (PMID:34001980) showing C3 but not C5 is critical","pmids":["23943789"],"is_preprint":false},{"year":2018,"finding":"HTRA1 serine protease cleaves EFEMP1 as a novel substrate; HTRA1 protein level is increased in high-risk (10q26) RPE cells, accompanied by increased EFEMP1 proteolytic processing.","method":"Proteomic comparison of RPE cells with/without high-risk HTRA1 allele, identification of EFEMP1 as HTRA1 cleavage target","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — proteomics-based substrate identification in RPE cells, single lab, no in vitro reconstitution of cleavage reported in abstract","pmids":["29730901"],"is_preprint":false},{"year":2011,"finding":"In glioblastoma, EFEMP1 overexpression reduces EGFR protein levels and attenuates AKT signaling, suppresses VEGFA expression and angiogenesis, and inhibits tumor formation when EFEMP1 protein is mixed with cells prior to implantation or injected around established xenografts, indicating it acts in the extracellular compartment; VEGFA re-expression partially restores tumor onset but not overall growth rate.","method":"EFEMP1 overexpression/knockdown in glioma cell lines, subcutaneous and intracranial xenograft models, exogenous recombinant protein treatment, ectopic VEGFA rescue experiment, Western blot for EGFR and p-AKT","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo approaches including rescue experiment, knockdown/overexpression, and exogenous protein treatment in a single study","pmids":["21955618"],"is_preprint":false},{"year":2014,"finding":"EFEMP1 promotes temozolomide resistance in glioblastoma via γ-secretase-mediated activation of the Notch pathway; silencing EFEMP1 sensitizes cells to TMZ while overexpression causes resistance; γ-secretase inhibitor RO4929097 partially sensitizes cells to TMZ in vitro and in vivo.","method":"TMZ-resistant glioblastoma cell line engineering, EFEMP1 siRNA/overexpression, γ-secretase inhibitor treatment, in vitro and in vivo survival assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement via pharmacological inhibition of Notch/γ-secretase with functional rescue, in vitro and in vivo readouts, single lab","pmids":["24495907"],"is_preprint":false},{"year":2015,"finding":"EFEMP1 promotes osteosarcoma migration and invasion by directly upregulating MMP-2 expression; EFEMP1 is induced by oncogenic AEG-1 via NF-κB signaling pathway, placing EFEMP1 as a mediator between AEG-1 and MMP-2.","method":"EFEMP1 siRNA, plasmid transfection, purified EFEMP1 protein treatment in osteosarcoma cells, NF-κB inhibitor (PDTC), Western blot for MMP-2, invasion assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — pathway placement via pharmacological NF-κB inhibition, siRNA/OE with MMP-2 readout, exogenous protein experiments, single lab","pmids":["25987128"],"is_preprint":false},{"year":2016,"finding":"EFEMP1 inhibits migration of hepatocellular carcinoma cells by suppressing ERK1/2 phosphorylation, leading to decreased MMP-2 and MMP-9 expression; ERK1/2 inhibitor U0126 abrogates the increased migration caused by EFEMP1 siRNA knockdown.","method":"EFEMP1 siRNA, purified EFEMP1 protein treatment, ERK1/2 inhibitor U0126, Western blot for ERK1/2, MMP-2, MMP-9, migration assays","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — pharmacological pathway validation via ERK inhibitor rescue plus siRNA and exogenous protein approaches, single lab","pmids":["27108677"],"is_preprint":false},{"year":2016,"finding":"In endometrial carcinoma, estrogen/ERα signaling directly binds to an estrogen response element (ERE) in the EFEMP1 promoter and represses EFEMP1 expression; EFEMP1 in turn inhibits epithelial-mesenchymal transition (EMT) by suppressing Wnt/β-catenin signaling targets (Cyclin-D1, c-Myc, Vimentin, Snail).","method":"Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, EFEMP1 overexpression/knockdown, Wnt pathway inhibitor XAV93920 and activator LiCl, in vitro EMT marker analysis","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct ChIP and luciferase reporter establish ERα binding to EFEMP1 promoter ERE; functional pathway placement via inhibitor/activator rescue, single lab with multiple orthogonal methods","pmids":["27015552"],"is_preprint":false},{"year":2003,"finding":"The FBLN3 proximal promoter is contained within 425 bp upstream of exon 1; important regulatory elements include three Sp1-binding sites, a trans-activating Tant motif, and an estrogen response element (ERE) that acts as a trans-repressor; fibulin-3 is expressed in murine and human RPE and in the outer and inner nuclear layers of the retina; estrogen modifies EFEMP1 expression in ARPE-19 cells.","method":"Reporter deletion-mutation luciferase transfection assays, in situ hybridization, RT-PCR, estrogen treatment of COS-7 and ARPE-19 cells","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter dissection by reporter assay plus direct localization by in situ hybridization, single lab","pmids":["14578376"],"is_preprint":false},{"year":2021,"finding":"Three novel EFEMP1 variants causing juvenile open-angle glaucoma (JOAG) all produce significant intracellular protein aggregation and retention in COS7 cells compared to wild-type; the degree of intracellular retention correlates with disease severity/phenotype across different EFEMP1 mutations.","method":"Transient transfection of COS7 cells with EFEMP1 variant constructs, fluorescence microscopy for intracellular accumulation","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cell-based protein retention assay across multiple variants, single lab; supports mechanism but no structural or biochemical follow-up","pmids":["34923728"],"is_preprint":false},{"year":2022,"finding":"A loss-of-function cysteine mutation C55R in EFEMP1 forms aberrant extracellular disulfide-linked homodimers, driven by new availability of Cys70 on adjacent monomers; single cysteine mutations near Cys55 (Cys29, Cys42, Cys48, Cys61, Cys70, Cys159, Cys171) also produce similar disulfide-linked dimers; F3 knockout RPE cells show reduced MMP-2 levels and reduced collagen VI ECM filament formation, both partially rescued by wild-type but not C55R F3 re-expression.","method":"Dual cysteine mutagenesis, non-reducing SDS-PAGE, F3 knockout RPE cells (CRISPR), Western blot for MMP-2, collagen VI immunostaining, rescue experiments with WT and C55R constructs","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis series with structural inference, KO cell rescue experiment, multiple ECM functional readouts, single lab with orthogonal methods","pmids":["35998264"],"is_preprint":false},{"year":2021,"finding":"NLRP3 inflammasome activation is a critical mediator of basal laminar deposit (BLamD) formation in R345W Efemp1 knockin mice; R345W+/+ mice show increased Muller gliosis, subretinal Iba-1+ cells, elevated Nlrp3 immunoreactivity, and transcriptional upregulation of complement C3, Nlrp3, pro-Il1b, and pro-caspase-1 in RPE/choroid; genetic elimination of Nlrp3 or Casp1 significantly reduces BLamD size and coverage.","method":"Double-mutant mouse genetics (R345W+/+:Nlrp3-/- and R345W+/+:Casp1-/-), histopathology, immunofluorescence, RT-qPCR for inflammasome components in RPE/choroid","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with double-knockout mice, multiple molecular readouts, single lab with rigorous in vivo design","pmids":["41198612"],"is_preprint":false},{"year":2024,"finding":"Wild-type fibulin-3 reduces intracellular actin stress fiber formation and extracellular fibronectin levels in human trabecular meshwork (TM) cells by inhibiting Rho/ROCK signaling; TGFβ1 upregulates fibulin-3 protein in TM cells via Rho/ROCK; overexpression of a stop-codon EFEMP1 mutant (p.X494Q) has opposite effects, increasing IOP and fibronectin in rat eyes.","method":"Overexpression of WT and mutant EFEMP1 in human TM cells and rat eyes, actin stress fiber staining, fibronectin Western blot, IOP measurement, Rho/ROCK pathway analysis","journal":"Experimental eye research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct pathway placement via Rho/ROCK signaling with in vitro and in vivo evidence, single lab, multiple readouts","pmids":["38467175"],"is_preprint":false},{"year":2024,"finding":"Fibulin-3 is required for normal elastic fiber organization in the extrahepatic bile duct (EHBD); Efemp1+/- mouse ducts show approximately half the normal elastin fiber density and altered mechanical properties (increased stretch), similar to elastase-treated ducts and neonatal ducts.","method":"Histology/staining for elastic fibers in mouse, rat, and human EHBD; pressure myography of Efemp1+/- vs wild-type ducts; elastase treatment comparison","journal":"JHEP reports : innovation in hepatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic haploinsufficiency model with direct mechanical functional readout (pressure myography) and histological quantification, multiple species comparison","pmids":["39717503"],"is_preprint":false},{"year":2025,"finding":"In hepatic stellate cells, fibulin-3 (EFEMP1) depletion impairs focal adhesions, FAK phosphorylation, fibronectin network formation, and cell migration, establishing EFEMP1 as a regulator of focal adhesion dynamics and migration in these cells.","method":"Gene silencing (EFEMP1 knockdown) in hepatic stellate cells, Western blot for FAK phosphorylation, immunostaining for focal adhesions and fibronectin network, migration assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — loss-of-function with specific cellular phenotypes and molecular readouts, single lab, multiple orthogonal assays","pmids":["40171970"],"is_preprint":false},{"year":2023,"finding":"EFEMP1 promotes scleral remodeling in form-deprivation myopia by regulating the PI3K/AKT/MMP2 axis in scleral fibroblasts; AAV-mediated shEFEMP1 injection under Tenon's capsule delays myopia progression and posterior scleral remodeling in guinea pigs, while EFEMP1 overexpression exacerbates myopia and collagen fiber thinning.","method":"Lentiviral EFEMP1 overexpression/shRNA in primary scleral fibroblasts, transcriptome sequencing, PI3K inhibitor LY294002, AAV injection in guinea pig form-deprivation myopia model, refraction/axial length measurement, histology","journal":"Biochimica et biophysica acta. Molecular basis of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo AAV model plus in vitro pathway inhibitor confirmation of PI3K/AKT/MMP2 axis, single lab, multiple methods","pmids":["38101653"],"is_preprint":false},{"year":2022,"finding":"EFEMP1 binds to STEAP1 and enables Wnt/β-catenin and TGF-β/Smad2/3 signaling to promote EMT in osteosarcoma cells; exogenous EFEMP1 fails to activate these pathways or EMT when STEAP1 is knocked down.","method":"EFEMP1 overexpression/knockdown, STEAP1 knockdown, Western blot for Wnt/β-catenin and TGF-β/Smad2/3 pathway markers, EMT marker analysis, rescue experiments","journal":"Journal of bone oncology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — epistasis/rescue experiment places STEAP1 downstream of EFEMP1 with pathway readouts, single lab","pmids":["36388640"],"is_preprint":false},{"year":2022,"finding":"FBLN1 (fibulin-1) interacts with EFEMP1 protein and increases its protein stability; FBLN1-mediated suppression of ferroptosis in ectopic endometrial stromal cells requires EFEMP1, as EFEMP1 silencing reverses FBLN1-induced protection from ferroptosis, cell death, and migration.","method":"Co-immunoprecipitation (FBLN1-EFEMP1 interaction), EFEMP1 siRNA rescue in FBLN1-overexpressing cells, ferroptosis markers (Fe2+, lipid ROS, MDA, GPX4, GSH), cell viability assays","journal":"BioMed research international","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP for interaction plus epistasis rescue experiment with multiple ferroptosis readouts, single lab","pmids":["35127942"],"is_preprint":false},{"year":2025,"finding":"HIPK4 kinase phosphorylates the transcription factor TAp63 at Ser395, which decreases EFEMP1 expression; this HIPK4-TAp63-EFEMP1 axis promotes cutaneous squamous cell carcinoma progression, and HIPK4 knockdown tumor suppression is reversed by EFEMP1 knockdown.","method":"Co-IP and GST-pulldown (HIPK4-TAp63 interaction), ChIP and dual luciferase reporter assay (TAp63 binding to EFEMP1 promoter), phospho-mutagenesis (TAp63 Ser395), HIPK4/EFEMP1 knockdown rescue experiments, mouse tumor models","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — kinase-substrate interaction by pulldown, phosphosite mapping, ChIP and reporter for transcriptional regulation, and genetic epistasis rescue, single lab with multiple orthogonal methods","pmids":["40316017"],"is_preprint":false},{"year":2020,"finding":"miR-9 directly targets EFEMP1 in normal fibroblasts (confirmed by luciferase reporter assay); miR-9-induced EFEMP1 silencing recapitulates conversion of normal fibroblasts to cancer-associated fibroblast (CAF)-like cells with increased migration, invasion, and ability to induce cisplatin resistance in breast cancer cells.","method":"Luciferase reporter assay for miR-9 targeting of EFEMP1, siRNA knockdown of EFEMP1, migration/invasion assays, co-culture conditioned medium cisplatin resistance assay","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct miRNA target validation by luciferase reporter plus loss-of-function phenotypic recapitulation, single lab","pmids":["32972039"],"is_preprint":false},{"year":2019,"finding":"EFEMP1 suppresses hepatocellular carcinoma cell proliferation by promoting Semaphorin 3B (SEMA3B) expression via the Axon guidance pathway; EFEMP1 promotes HCC cell apoptosis mainly through the mitochondrial apoptosis pathway.","method":"Lentiviral EFEMP1 overexpression in HCC cells, gene chip expression profiling, GO/pathway analysis, SEMA3B siRNA rescue, apoptosis assays (Annexin V), in vivo xenograft","journal":"Cancer medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement relies primarily on gene chip analysis with siRNA rescue, limited mechanistic biochemistry reported in abstract, single lab","pmids":["30972979"],"is_preprint":false},{"year":2023,"finding":"Different EFEMP1 missense mutants (p.Met59Leu, p.Arg140Trp, p.Arg345Trp) each increase intracellular protein aggregation but differentially activate ER stress markers (ATF4, GRP78/94, CHOP) and phosphorylation of CREB, AKT, p44/42, and STAT3, demonstrating mutation-dependent signaling consequences.","method":"Immunoprecipitation and Western blot for intracellular aggregation, ER stress marker Western blots, phospho-specific antibodies for downstream kinases in HEK293T cells; intravitreal Ad5-EFEMP1 injection in rat eyes for IOP and RGC measurement","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple mutants compared with specific ER stress and signaling readouts in vitro plus in vivo IOP functional validation, single lab","pmids":["38083999"],"is_preprint":false}],"current_model":"EFEMP1 (fibulin-3) is a secreted ECM glycoprotein whose wild-type form is efficiently secreted, where it binds TIMP-3 and can engage EGFR to activate MAPK/AKT signaling; disease-causing mutations (notably R345W) cause protein misfolding, impaired disulfide bonding in EGF-like domain 6, reduced secretion, and intracellular retention/aggregation that drives sub-RPE basal deposit formation via complement C3 and NLRP3 inflammasome-dependent mechanisms, while in various cellular contexts EFEMP1 modulates MMP activity, Rho/ROCK-dependent actin cytoskeleton and fibronectin remodeling, Wnt/β-catenin, Notch/γ-secretase, and PI3K/AKT/VEGF signaling to regulate cell migration, invasion, angiogenesis, and apoptosis in a cell-context-dependent manner."},"narrative":{"mechanistic_narrative":"EFEMP1 (fibulin-3) is a secreted extracellular matrix glycoprotein that organizes ECM architecture and modulates multiple signaling pathways governing cell migration, invasion, angiogenesis, and apoptosis in a cell-context-dependent manner [PMID:21955618, PMID:35998264, PMID:39717503]. Wild-type fibulin-3 is efficiently secreted, where it binds the macular-degeneration protein TIMP-3 through TIMP-3's COOH-terminus [PMID:15123717] and supports ECM functions including MMP-2 production and collagen VI filament assembly [PMID:35998264] and elastic-fiber organization in tissues such as the extrahepatic bile duct [PMID:39717503]. In the extracellular compartment EFEMP1 engages EGFR competitively with EGF, triggering EGFR autophosphorylation and downstream AKT and p44/p42 MAPK activation [PMID:19804359], and across cancer contexts it bidirectionally tunes MMP expression, Wnt/β-catenin and TGF-β/Smad signaling (in part through binding STEAP1), ERK1/2, PI3K/AKT/VEGF, and Notch/γ-secretase pathways to either suppress or promote tumor behavior depending on cell type [PMID:21955618, PMID:25987128, PMID:27015552, PMID:36388640]. EFEMP1 also restrains Rho/ROCK-dependent actin stress-fiber and fibronectin remodeling and regulates focal-adhesion dynamics and FAK phosphorylation [PMID:38467175, PMID:40171970]. The single missense mutation Arg345Trp causes the inherited maculopathies Malattia Leventinese and Doyne honeycomb retinal dystrophy [PMID:10369267]; this and other pathogenic substitutions disrupt native disulfide bonding in EGF-like domain 6, impair secretion, and cause intracellular retention and aggregation [PMID:12242346, PMID:22031286, PMID:34923728, PMID:38083999]. In R345W knockin mice the misfolded protein and TIMP-3 accumulate in sub-RPE basal deposits, and deposit formation depends critically on complement C3 (but not C5) and on NLRP3 inflammasome/caspase-1 activation [PMID:17666404, PMID:17664227, PMID:23943789, PMID:41198612]. Distinct loss-of-function cysteine mutations instead drive aberrant extracellular disulfide-linked homodimers with loss of ECM function [PMID:35998264].","teleology":[{"year":1999,"claim":"Establishing EFEMP1 as a disease gene answered whether a single locus underlies inherited macular drusen dystrophies, linking the protein to sub-RPE deposit disease.","evidence":"Positional cloning and candidate sequencing in families, mutation absent in controls","pmids":["10369267"],"confidence":"High","gaps":["Did not establish the cellular mechanism by which R345W causes drusen","Did not address the protein's normal function"]},{"year":2002,"claim":"Showing that R345W is misfolded and poorly secreted while accumulating in RPE cells reframed the disease as a protein-trafficking defect rather than simple loss of an ECM component.","evidence":"Secretion assays in transfected cells and immunolocalization in human ML/AMD eye sections","pmids":["12242346"],"confidence":"High","gaps":["Did not define the structural basis of misfolding","Did not show how retained protein triggers deposit formation"]},{"year":2003,"claim":"Mapping the FBLN3 promoter and showing retinal expression and estrogen responsiveness established how EFEMP1 transcription is controlled and where the protein is normally made.","evidence":"Reporter deletion assays, in situ hybridization, RT-PCR, estrogen treatment of ARPE-19/COS-7 cells","pmids":["14578376"],"confidence":"Medium","gaps":["Promoter dissection from a single lab","Functional consequence of estrogen regulation in vivo unresolved"]},{"year":2004,"claim":"Identifying TIMP-3 as a fibulin-3 binding partner connected two macular-degeneration proteins and gave EFEMP1 a defined extracellular interaction in the subretinal space.","evidence":"In vivo binding screen, co-IP/pulldown, co-localization, TIMP-3 C-terminus domain mapping","pmids":["15123717"],"confidence":"High","gaps":["Functional consequence of the interaction not defined","Whether interaction is altered by R345W not tested"]},{"year":2007,"claim":"R345W knockin mice answered whether the mutation is sufficient to cause disease in vivo, recapitulating sub-RPE deposits containing fibulin-3 and TIMP-3 with complement activation.","evidence":"Knockin mouse histopathology, EM, immunofluorescence, complement assays (two concurrent studies)","pmids":["17666404","17664227"],"confidence":"High","gaps":["Did not establish causality of complement in deposit formation","Mechanism linking retained protein to deposits unresolved"]},{"year":2009,"claim":"Demonstrating that EFEMP1 binds EGFR competitively with EGF and activates AKT/MAPK gave the protein a defined extracellular signaling activity beyond a structural ECM role.","evidence":"Competitive binding assay, site-specific phospho-Western blots, EGFR kinase inhibitor in pancreatic carcinoma cells","pmids":["19804359"],"confidence":"High","gaps":["Whether EGFR engagement is direct or via co-receptor not resolved","Relevance to retinal disease untested"]},{"year":2011,"claim":"Pinpointing reduced native disulfide bonding in EGF-like domain 6 and rescue by proteostasis manipulation defined the biochemical basis of the secretion defect.","evidence":"Luciferase secretion assays, position-345 mutant panel, disulfide analysis, temperature/translation attenuation rescue","pmids":["22031286"],"confidence":"High","gaps":["Did not resolve full folded structure of domain 6","Did not link disulfide defect to in vivo deposit formation"]},{"year":2011,"claim":"Glioblastoma experiments showed EFEMP1 acts extracellularly to lower EGFR, attenuate AKT, and suppress VEGFA/angiogenesis, establishing a tumor-suppressive, anti-angiogenic role in this context.","evidence":"Overexpression/knockdown, xenografts, exogenous protein treatment, VEGFA rescue, Western blot","pmids":["21955618"],"confidence":"High","gaps":["Apparently opposite EGFR effect versus pancreatic carcinoma not reconciled","Receptor-level mechanism of EGFR downregulation unresolved"]},{"year":2013,"claim":"Genetic ablation of C3 (but not C5) in R345W mice answered whether complement is causal, showing C3 is required for basal deposit formation.","evidence":"Double-mutant mouse genetics, Bruch's membrane proteomics, histopathology","pmids":["23943789"],"confidence":"High","gaps":["How retained fibulin-3 triggers complement activation unresolved","Upstream initiator of C3 activation not defined"]},{"year":2014,"claim":"Linking EFEMP1 to γ-secretase/Notch-mediated temozolomide resistance placed it within a druggable survival pathway in glioblastoma.","evidence":"TMZ-resistant cell engineering, siRNA/overexpression, γ-secretase inhibitor, survival assays in vitro and in vivo","pmids":["24495907"],"confidence":"Medium","gaps":["Direct biochemical link between EFEMP1 and Notch activation not shown","Single lab"]},{"year":2016,"claim":"Defining context-dependent MMP regulation showed EFEMP1 can promote (osteosarcoma, MMP-2 via AEG-1/NF-κB) or suppress (HCC, MMP-2/9 via ERK1/2) invasion depending on cell type, and that ERα directly represses EFEMP1 to relieve Wnt/β-catenin-driven EMT in endometrial carcinoma.","evidence":"siRNA/overexpression, exogenous protein, pathway inhibitors (PDTC, U0126, XAV93920/LiCl), ChIP and luciferase reporter, EMT/MMP readouts","pmids":["25987128","27108677","27015552"],"confidence":"Medium","gaps":["Determinants of context-dependent opposite effects unresolved","Direct receptor mediating each effect not defined"]},{"year":2018,"claim":"Identifying EFEMP1 as an HTRA1 cleavage substrate connected the protein to the high-risk 10q26 AMD locus through increased proteolytic processing.","evidence":"Proteomic comparison of RPE cells with/without high-risk HTRA1 allele","pmids":["29730901"],"confidence":"Medium","gaps":["No in vitro reconstitution of cleavage reported","Functional consequence of cleavage fragments unresolved"]},{"year":2021,"claim":"NLRP3/caspase-1 epistasis in R345W mice established inflammasome signaling as a second critical mediator of basal laminar deposit formation alongside complement.","evidence":"R345W:Nlrp3-/- and R345W:Casp1-/- double mutants, histopathology, immunofluorescence, RT-qPCR in RPE/choroid","pmids":["41198612"],"confidence":"High","gaps":["Trigger of inflammasome activation by retained fibulin-3 unknown","Relationship between C3 and NLRP3 pathways unresolved"]},{"year":2021,"claim":"Showing that JOAG-causing variants all aggregate intracellularly, with retention correlating with severity, extended the misfolding/retention mechanism beyond retinal disease to glaucoma.","evidence":"Transient transfection of variants in COS7 cells, fluorescence microscopy","pmids":["34923728"],"confidence":"Medium","gaps":["No structural or biochemical follow-up","How retention causes raised IOP unresolved"]},{"year":2022,"claim":"Distinguishing loss-of-function cysteine mutations that form aberrant extracellular disulfide-linked homodimers, plus KO-cell rescue, defined fibulin-3's normal ECM role in MMP-2 and collagen VI assembly and a distinct dimerization mechanism of dysfunction.","evidence":"Dual cysteine mutagenesis, non-reducing SDS-PAGE, CRISPR KO RPE cells, MMP-2/collagen VI readouts, WT vs C55R rescue","pmids":["35998264"],"confidence":"High","gaps":["In vivo consequence of homodimerization untested","Single lab"]},{"year":2022,"claim":"Identifying STEAP1 as an EFEMP1 binding partner required for Wnt/β-catenin and TGF-β/Smad-driven EMT provided a receptor-level handle on EFEMP1 pro-tumor signaling in osteosarcoma.","evidence":"Overexpression/knockdown, STEAP1 knockdown epistasis, pathway/EMT Western blots, rescue","pmids":["36388640"],"confidence":"Medium","gaps":["Direct EFEMP1-STEAP1 binding not biochemically mapped","Single lab"]},{"year":2022,"claim":"Showing FBLN1 binds and stabilizes EFEMP1 to suppress ferroptosis in endometrial stromal cells added a protein-stability partnership and a redox-survival role.","evidence":"Co-IP, EFEMP1 siRNA rescue in FBLN1-overexpressing cells, ferroptosis markers, viability assays","pmids":["35127942"],"confidence":"Medium","gaps":["Mechanism of stabilization unresolved","Single lab, reciprocal validation limited"]},{"year":2023,"claim":"Comparing multiple missense mutants showed they share intracellular aggregation but differentially activate ER-stress and downstream kinase signaling, indicating mutation-specific gain-of-function consequences.","evidence":"IP/Western for aggregation, ER-stress markers, phospho-antibodies in HEK293T; intravitreal Ad5-EFEMP1 in rat eyes","pmids":["38083999"],"confidence":"Medium","gaps":["Causal link between specific ER-stress signature and disease phenotype unresolved","Single lab"]},{"year":2023,"claim":"Demonstrating EFEMP1 regulation of scleral remodeling via PI3K/AKT/MMP2, with AAV knockdown delaying myopia, broadened its role to ocular ECM remodeling beyond the RPE.","evidence":"Lentiviral OE/shRNA in scleral fibroblasts, transcriptomics, PI3K inhibitor, AAV in guinea pig myopia model, histology","pmids":["38101653"],"confidence":"Medium","gaps":["Receptor mediating EFEMP1 signaling in sclera not defined","Single lab"]},{"year":2024,"claim":"Defining fibulin-3 control of Rho/ROCK-dependent stress fibers and fibronectin in trabecular meshwork, and its requirement for elastic-fiber organization in the bile duct, established core cytoskeletal/ECM-remodeling functions of the wild-type protein.","evidence":"WT/mutant OE in TM cells and rat eyes with IOP/fibronectin readouts; Efemp1+/- mouse bile-duct histology and pressure myography","pmids":["38467175","39717503"],"confidence":"High","gaps":["Molecular link between fibulin-3 and Rho/ROCK not defined","Whether bile-duct elastin role applies to other tissues unresolved"]},{"year":2025,"claim":"Loss-of-function in hepatic stellate cells and transcriptional control by the HIPK4-TAp63 and miR-9 axes refined how EFEMP1 abundance is set and how it controls focal-adhesion dynamics, migration, and tumor progression.","evidence":"EFEMP1 knockdown with FAK/focal-adhesion/fibronectin readouts (stellate cells); HIPK4-TAp63 pulldown, ChIP/reporter, phospho-mutagenesis, knockdown rescue and tumor models; miR-9 luciferase target validation","pmids":["40171970","40316017","32972039"],"confidence":"Medium","gaps":["Direct downstream effector of focal-adhesion regulation unresolved","Integration of the multiple upstream regulators in vivo unresolved"]},{"year":null,"claim":"How intracellular retention of misfolded EFEMP1 mechanistically triggers complement C3 and NLRP3 inflammasome activation in the RPE, and what reconciles its opposite signaling outcomes across cell types, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined molecular link between ER retention and complement/inflammasome activation","No unifying receptor model explaining context-dependent pro- vs anti-tumor effects","No high-resolution structure of EGF-like domain 6 explaining disulfide-dependent misfolding"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[16,19]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,9,18]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,2,9]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[16,19]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,6,27]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,18,22]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[16,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,3,7,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,17]}],"complexes":[],"partners":["TIMP3","EGFR","HTRA1","STEAP1","FBLN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q12805","full_name":"EGF-containing fibulin-like extracellular matrix protein 1","aliases":["Extracellular protein S1-5","Fibrillin-like protein","Fibulin-3","FIBL-3"],"length_aa":493,"mass_kda":54.6,"function":"Binds EGFR, the EGF receptor, inducing EGFR autophosphorylation and the activation of downstream signaling pathways. May play a role in cell adhesion and migration. May function as a negative regulator of chondrocyte differentiation. In the olfactory epithelium, it may regulate glial cell migration, differentiation and the ability of glial cells to support neuronal neurite outgrowth","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q12805/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EFEMP1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EFEMP1","total_profiled":1310},"omim":[{"mim_id":"620780","title":"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE ID; ARCL1D","url":"https://www.omim.org/entry/620780"},{"mim_id":"611276","title":"GLAUCOMA 1, OPEN ANGLE, H; GLC1H","url":"https://www.omim.org/entry/611276"},{"mim_id":"604633","title":"EGF-CONTAINING FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 2; EFEMP2","url":"https://www.omim.org/entry/604633"},{"mim_id":"604580","title":"FIBULIN 5; FBLN5","url":"https://www.omim.org/entry/604580"},{"mim_id":"603075","title":"MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1","url":"https://www.omim.org/entry/603075"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":977.9}],"url":"https://www.proteinatlas.org/search/EFEMP1"},"hgnc":{"alias_symbol":["S1-5","FBLN3","MTLV"],"prev_symbol":["DHRD","FBNL"]},"alphafold":{"accession":"Q12805","domains":[{"cath_id":"-","chopping":"32-70","consensus_level":"high","plddt":75.2654,"start":32,"end":70},{"cath_id":"2.10.25.10","chopping":"162-213","consensus_level":"high","plddt":88.6037,"start":162,"end":213},{"cath_id":"2.10.25.10","chopping":"216-255","consensus_level":"medium","plddt":90.1747,"start":216,"end":255},{"cath_id":"2.10.25.10","chopping":"257-293","consensus_level":"medium","plddt":88.1524,"start":257,"end":293},{"cath_id":"2.10.25.10","chopping":"296-333","consensus_level":"medium","plddt":90.8829,"start":296,"end":333},{"cath_id":"2.60.40.60","chopping":"342-487","consensus_level":"high","plddt":90.2418,"start":342,"end":487}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12805","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q12805-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q12805-F1-predicted_aligned_error_v6.png","plddt_mean":76.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EFEMP1","jax_strain_url":"https://www.jax.org/strain/search?query=EFEMP1"},"sequence":{"accession":"Q12805","fasta_url":"https://rest.uniprot.org/uniprotkb/Q12805.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q12805/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12805"}},"corpus_meta":[{"pmid":"10369267","id":"PMC_10369267","title":"A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10369267","citation_count":382,"is_preprint":false},{"pmid":"12242346","id":"PMC_12242346","title":"Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12242346","citation_count":185,"is_preprint":false},{"pmid":"34936728","id":"PMC_34936728","title":"METTL1-m7 G-EGFR/EFEMP1 axis promotes the bladder cancer development.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34936728","citation_count":159,"is_preprint":false},{"pmid":"15123717","id":"PMC_15123717","title":"Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15123717","citation_count":136,"is_preprint":false},{"pmid":"17666404","id":"PMC_17666404","title":"The R345W mutation in EFEMP1 is pathogenic and causes AMD-like deposits in mice.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17666404","citation_count":116,"is_preprint":false},{"pmid":"17664227","id":"PMC_17664227","title":"Formation and progression of sub-retinal pigment epithelium deposits in Efemp1 mutation knock-in mice: a model for the early pathogenic course of macular degeneration.","date":"2007","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17664227","citation_count":101,"is_preprint":false},{"pmid":"19208748","id":"PMC_19208748","title":"EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19208748","citation_count":85,"is_preprint":false},{"pmid":"29730901","id":"PMC_29730901","title":"HTRA1, an age-related macular degeneration protease, processes extracellular matrix proteins EFEMP1 and TSP1.","date":"2018","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/29730901","citation_count":85,"is_preprint":false},{"pmid":"19115204","id":"PMC_19115204","title":"Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19115204","citation_count":83,"is_preprint":false},{"pmid":"19804359","id":"PMC_19804359","title":"EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells.","date":"2009","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19804359","citation_count":74,"is_preprint":false},{"pmid":"17671114","id":"PMC_17671114","title":"Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.","date":"2007","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/17671114","citation_count":74,"is_preprint":false},{"pmid":"21163514","id":"PMC_21163514","title":"EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer in vivo.","date":"2010","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21163514","citation_count":70,"is_preprint":false},{"pmid":"19898900","id":"PMC_19898900","title":"Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.","date":"2009","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19898900","citation_count":69,"is_preprint":false},{"pmid":"21955618","id":"PMC_21955618","title":"EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21955618","citation_count":63,"is_preprint":false},{"pmid":"9106159","id":"PMC_9106159","title":"Human fibulin-1D: molecular cloning, expression and similarity with S1-5 protein, a new member of the fibulin gene family.","date":"1997","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9106159","citation_count":57,"is_preprint":false},{"pmid":"21571867","id":"PMC_21571867","title":"EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21571867","citation_count":55,"is_preprint":false},{"pmid":"25987128","id":"PMC_25987128","title":"EFEMP1 promotes the migration and invasion of osteosarcoma via MMP-2 with induction by AEG-1 via NF-κB signaling pathway.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25987128","citation_count":52,"is_preprint":false},{"pmid":"26162006","id":"PMC_26162006","title":"Exome Sequencing Identifies a Missense Variant in EFEMP1 Co-Segregating in a Family with Autosomal Dominant Primary Open-Angle Glaucoma.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26162006","citation_count":52,"is_preprint":false},{"pmid":"8817347","id":"PMC_8817347","title":"The gene responsible for autosomal dominant Doyne's honeycomb retinal dystrophy (DHRD) maps to chromosome 2p16.","date":"1996","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8817347","citation_count":48,"is_preprint":false},{"pmid":"23943789","id":"PMC_23943789","title":"Mouse genetics and proteomic analyses demonstrate a critical role for complement in a model of DHRD/ML, an inherited macular degeneration.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23943789","citation_count":45,"is_preprint":false},{"pmid":"24495907","id":"PMC_24495907","title":"EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24495907","citation_count":45,"is_preprint":false},{"pmid":"28292024","id":"PMC_28292024","title":"MiR-338-5p suppresses proliferation, migration, invasion, and promote apoptosis of glioblastoma cells by directly targeting EFEMP1.","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28292024","citation_count":44,"is_preprint":false},{"pmid":"27108677","id":"PMC_27108677","title":"EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27108677","citation_count":41,"is_preprint":false},{"pmid":"15512998","id":"PMC_15512998","title":"Association of EFEMP1 with malattia leventinese and age-related macular degeneration: a mini-review.","date":"2004","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15512998","citation_count":39,"is_preprint":false},{"pmid":"34923728","id":"PMC_34923728","title":"EFEMP1 rare variants cause familial juvenile-onset open-angle glaucoma.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/34923728","citation_count":39,"is_preprint":false},{"pmid":"22031286","id":"PMC_22031286","title":"Compromised mutant EFEMP1 secretion associated with macular dystrophy remedied by proteostasis network alteration.","date":"2011","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22031286","citation_count":37,"is_preprint":false},{"pmid":"12915309","id":"PMC_12915309","title":"Cloning, expression and characterization of the murine Efemp1, a gene mutated in Doyne-Honeycomb retinal dystrophy.","date":"2003","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/12915309","citation_count":37,"is_preprint":false},{"pmid":"23840707","id":"PMC_23840707","title":"Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23840707","citation_count":36,"is_preprint":false},{"pmid":"19850834","id":"PMC_19850834","title":"A novel haplotype with the R345W mutation in the EFEMP1 gene associated with autosomal dominant drusen in a Japanese family.","date":"2009","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/19850834","citation_count":34,"is_preprint":false},{"pmid":"23470560","id":"PMC_23470560","title":"Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.","date":"2013","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/23470560","citation_count":34,"is_preprint":false},{"pmid":"10228006","id":"PMC_10228006","title":"Virus and autoimmunity: induction of autoimmune disease in mice by mouse T lymphotropic virus (MTLV) destroying CD4+ T cells.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10228006","citation_count":33,"is_preprint":false},{"pmid":"14578376","id":"PMC_14578376","title":"Transcriptional regulation and expression of the dominant drusen gene FBLN3 (EFEMP1) in mammalian retina.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/14578376","citation_count":28,"is_preprint":false},{"pmid":"27351229","id":"PMC_27351229","title":"EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27351229","citation_count":27,"is_preprint":false},{"pmid":"19913326","id":"PMC_19913326","title":"Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma.","date":"2009","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/19913326","citation_count":26,"is_preprint":false},{"pmid":"35127942","id":"PMC_35127942","title":"Upregulated Fibulin-1 Increased Endometrial Stromal Cell Viability and Migration by Repressing EFEMP1-Dependent Ferroptosis in Endometriosis.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/35127942","citation_count":25,"is_preprint":false},{"pmid":"30972979","id":"PMC_30972979","title":"Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B).","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30972979","citation_count":25,"is_preprint":false},{"pmid":"27015552","id":"PMC_27015552","title":"EFEMP1 is repressed by estrogen and inhibits the epithelial-mesenchymal transition via Wnt/β-catenin signaling in endometrial carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27015552","citation_count":24,"is_preprint":false},{"pmid":"8812496","id":"PMC_8812496","title":"Structure and chromosomal assignment of the human S1-5 gene (FBNL) that is highly homologous to fibrillin.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8812496","citation_count":23,"is_preprint":false},{"pmid":"33584252","id":"PMC_33584252","title":"EFEMP1 Overexpression Contributes to Neovascularization in Age-Related Macular Degeneration.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33584252","citation_count":22,"is_preprint":false},{"pmid":"25211630","id":"PMC_25211630","title":"Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.","date":"2014","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25211630","citation_count":22,"is_preprint":false},{"pmid":"15218514","id":"PMC_15218514","title":"Analysis of the EFEMP1 gene in individuals and families with early onset drusen.","date":"2005","source":"Eye (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15218514","citation_count":21,"is_preprint":false},{"pmid":"10087203","id":"PMC_10087203","title":"Radiation hybrid mapping of chromosomal region 2p15-p16: integration of expressed and polymorphic sequences maps at the Carney complex (CNC) and Doyne honeycomb retinal dystrophy (DHRD) loci.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10087203","citation_count":19,"is_preprint":false},{"pmid":"28085790","id":"PMC_28085790","title":"Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer.","date":"2017","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/28085790","citation_count":19,"is_preprint":false},{"pmid":"12427233","id":"PMC_12427233","title":"Analysis of the Arg345Trp disease-associated allele of the EFEMP1 gene in individuals with early onset drusen or familial age-related macular degeneration.","date":"2002","source":"Clinical & experimental ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12427233","citation_count":19,"is_preprint":false},{"pmid":"32972039","id":"PMC_32972039","title":"miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32972039","citation_count":18,"is_preprint":false},{"pmid":"34204134","id":"PMC_34204134","title":"Utility of EFEMP1 in the Prediction of Oncologic Outcomes of Urothelial Carcinoma.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34204134","citation_count":15,"is_preprint":false},{"pmid":"27270657","id":"PMC_27270657","title":"HIF2α/EFEMP1 cascade mediates hypoxic effects on breast cancer stem cell hierarchy.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27270657","citation_count":15,"is_preprint":false},{"pmid":"33020971","id":"PMC_33020971","title":"The novel form of amyloidosis derived from EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) preferentially affects the lower gastrointestinal tract of elderly femalesa.","date":"2020","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/33020971","citation_count":15,"is_preprint":false},{"pmid":"35998264","id":"PMC_35998264","title":"A loss-of-function cysteine mutant in fibulin-3 (EFEMP1) forms aberrant extracellular disulfide-linked homodimers and alters extracellular matrix composition.","date":"2022","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/35998264","citation_count":15,"is_preprint":false},{"pmid":"18791549","id":"PMC_18791549","title":"Retinal microstructure in patients with EFEMP1 retinal dystrophy evaluated by Fourier domain OCT.","date":"2008","source":"Eye (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18791549","citation_count":15,"is_preprint":false},{"pmid":"38101653","id":"PMC_38101653","title":"Targeting scleral remodeling and myopia development in form deprivation myopia through inhibition of EFEMP1 expression.","date":"2023","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38101653","citation_count":14,"is_preprint":false},{"pmid":"34958018","id":"PMC_34958018","title":"Plasma EFEMP1 Is Associated with Brain Aging and Dementia: The Framingham Heart Study.","date":"2022","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/34958018","citation_count":14,"is_preprint":false},{"pmid":"24080855","id":"PMC_24080855","title":"The EFEMP1 gene: a frequent target for epigenetic silencing in multiple human pituitary adenoma subtypes.","date":"2013","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24080855","citation_count":14,"is_preprint":false},{"pmid":"11384588","id":"PMC_11384588","title":"Dominant radial drusen and Arg345Trp EFEMP1 mutation.","date":"2001","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/11384588","citation_count":14,"is_preprint":false},{"pmid":"36388640","id":"PMC_36388640","title":"EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways.","date":"2022","source":"Journal of bone oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36388640","citation_count":13,"is_preprint":false},{"pmid":"10071196","id":"PMC_10071196","title":"Refined genetic and physical positioning of the gene for Doyne honeycomb retinal dystrophy (DHRD).","date":"1999","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10071196","citation_count":12,"is_preprint":false},{"pmid":"35946471","id":"PMC_35946471","title":"Association of EFEMP1 with juvenile-onset open angle glaucoma in a patient with concomitant COL11A1-related Stickler syndrome.","date":"2022","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35946471","citation_count":11,"is_preprint":false},{"pmid":"34001980","id":"PMC_34001980","title":"Complement C5 is not critical for the formation of sub-RPE deposits in Efemp1 mutant mice.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34001980","citation_count":11,"is_preprint":false},{"pmid":"30541486","id":"PMC_30541486","title":"Doyne honeycomb retinal dystrophy/malattia leventinese induced by EFEMP1 mutation in a Chinese family.","date":"2018","source":"BMC ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/30541486","citation_count":10,"is_preprint":false},{"pmid":"33131351","id":"PMC_33131351","title":"EFEMP1 in Direct Inguinal Hernia: correlation with TIMP3 and Regulation Toward Elastin Homoeostasis as Well as Fibroblast Mobility.","date":"2020","source":"Journal of investigative surgery : the official journal of the Academy of Surgical Research","url":"https://pubmed.ncbi.nlm.nih.gov/33131351","citation_count":10,"is_preprint":false},{"pmid":"36303838","id":"PMC_36303838","title":"The extracellular matrix protein fibulin-3/EFEMP1 promotes pleural mesothelioma growth by activation of PI3K/Akt signaling.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36303838","citation_count":10,"is_preprint":false},{"pmid":"30784281","id":"PMC_30784281","title":"FBLN3 inhibited the invasion and metastasis of colorectal cancer through the AKT/mTOR pathway.","date":"2019","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/30784281","citation_count":10,"is_preprint":false},{"pmid":"2831663","id":"PMC_2831663","title":"Mouse thymic virus (MTLV; murid herpesvirus 3) infection in athymic nude mice: evidence for a T lymphocyte requirement.","date":"1988","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/2831663","citation_count":10,"is_preprint":false},{"pmid":"38750770","id":"PMC_38750770","title":"Exploring ocular fibulin-3 (EFEMP1): Anatomical, age-related, and species perspectives.","date":"2024","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/38750770","citation_count":9,"is_preprint":false},{"pmid":"36891459","id":"PMC_36891459","title":"EFEMP1 is a potential biomarker of choroid thickness change in myopia.","date":"2023","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36891459","citation_count":9,"is_preprint":false},{"pmid":"25638659","id":"PMC_25638659","title":"Association of EFEMP1 gene polymorphisms with the risk of glioma: A hospital-based case-control study in a Chinese Han population.","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25638659","citation_count":9,"is_preprint":false},{"pmid":"23036572","id":"PMC_23036572","title":"Laser clearance of drusen deposit in patients with autosomal dominant drusen (p.Arg345Trp in EFEMP1).","date":"2012","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/23036572","citation_count":9,"is_preprint":false},{"pmid":"34763604","id":"PMC_34763604","title":"Systemic amyloidosis derived from EFEMP1 in a captive Tsushima leopard cat.","date":"2021","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34763604","citation_count":8,"is_preprint":false},{"pmid":"25111685","id":"PMC_25111685","title":"Malattia leventinese/Doyne honeycomb retinal dystrophy in a chinese family with mutation of the EFEMP1 gene.","date":"2014","source":"Retina (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/25111685","citation_count":8,"is_preprint":false},{"pmid":"27713911","id":"PMC_27713911","title":"Weaponizing human EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) for 21st century cancer therapeutics.","date":"2016","source":"Oncoscience","url":"https://pubmed.ncbi.nlm.nih.gov/27713911","citation_count":8,"is_preprint":false},{"pmid":"33807164","id":"PMC_33807164","title":"Loss-of-Function Variants in EFEMP1 Cause a Recognizable Connective Tissue Disorder Characterized by Cutis Laxa and Multiple Herniations.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33807164","citation_count":8,"is_preprint":false},{"pmid":"38083999","id":"PMC_38083999","title":"Novel mutation in EFEMP1 identified from two Chinese POAG families differentially activated endoplasmic reticulum stress markers and induced glaucoma in mouse.","date":"2023","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38083999","citation_count":7,"is_preprint":false},{"pmid":"25676403","id":"PMC_25676403","title":"[EFEMP1 suppresses growth and invasion of lung cancer cells 
by downregulating matrix metalloproteinase-7 expression].","date":"2015","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25676403","citation_count":7,"is_preprint":false},{"pmid":"28380465","id":"PMC_28380465","title":"Impact of interaction between the G870A and EFEMP1 gene polymorphism on glioma risk in Chinese Han population.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28380465","citation_count":7,"is_preprint":false},{"pmid":"26307682","id":"PMC_26307682","title":"Cell context-dependent dual effects of EFEMP1 stabilizes subpopulation equilibrium in responding to changes of in vivo growth environment.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26307682","citation_count":7,"is_preprint":false},{"pmid":"37062520","id":"PMC_37062520","title":"PUM2 regulates the formation of thoracic aortic dissection through EFEMP1.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37062520","citation_count":6,"is_preprint":false},{"pmid":"36114336","id":"PMC_36114336","title":"Impact of EFEMP1 on the survival outcome of biliary atresia in Thai infants.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36114336","citation_count":6,"is_preprint":false},{"pmid":"39717503","id":"PMC_39717503","title":"Biliary atresia susceptibility gene EFEMP1 regulates extrahepatic bile duct elastic fiber formation and mechanics.","date":"2024","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/39717503","citation_count":6,"is_preprint":false},{"pmid":"38467175","id":"PMC_38467175","title":"Stop codon variant in EFEMP1 is associated with primary open-angle glaucoma due to impaired regulation of aqueous humor outflow.","date":"2024","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/38467175","citation_count":6,"is_preprint":false},{"pmid":"27095449","id":"PMC_27095449","title":"Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms.","date":"2016","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27095449","citation_count":6,"is_preprint":false},{"pmid":"33381589","id":"PMC_33381589","title":"Hypermethylation of EFEMP1 in the Hippocampus May Be Related to the Deficit in Spatial Memory of Rat Neonates Triggered by Repeated Administration of Propofol.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/33381589","citation_count":6,"is_preprint":false},{"pmid":"2161418","id":"PMC_2161418","title":"Comparative sensitivity of infectivity assay and mouse antibody production (MAP) test for detection of mouse thymic virus (MTLV).","date":"1990","source":"Journal of virological methods","url":"https://pubmed.ncbi.nlm.nih.gov/2161418","citation_count":6,"is_preprint":false},{"pmid":"38200805","id":"PMC_38200805","title":"A Zebrafish Mutant in the Extracellular Matrix Protein Gene efemp1 as a Model for Spinal Osteoarthritis.","date":"2023","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/38200805","citation_count":5,"is_preprint":false},{"pmid":"38348595","id":"PMC_38348595","title":"EFEMP1 haploinsufficiency causes a Marfan-like hereditary connective tissue disorder.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/38348595","citation_count":5,"is_preprint":false},{"pmid":"39264138","id":"PMC_39264138","title":"A New Ocular Phenotype Combining Juvenile Glaucoma and Doyne Honeycomb Retinal Dystrophy (Malattia Leventinese) due to a Novel EFEMP1 Pathogenic Variant.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/39264138","citation_count":5,"is_preprint":false},{"pmid":"29035461","id":"PMC_29035461","title":"Evaluating EFEMP1 in Cerebrospinal Fluid and Serum as a Potential Diagnosis Biomarker for Meningiomas.","date":"2017","source":"Clinical laboratory","url":"https://pubmed.ncbi.nlm.nih.gov/29035461","citation_count":5,"is_preprint":false},{"pmid":"11262647","id":"PMC_11262647","title":"EFEMP1 is not associated with sporadic early onset drusen.","date":"2001","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11262647","citation_count":4,"is_preprint":false},{"pmid":"40171970","id":"PMC_40171970","title":"Proteomic analysis of liver fibrosis reveals EFEMP1 as a new modulator of focal adhesion and migration of hepatic stellate cells.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40171970","citation_count":4,"is_preprint":false},{"pmid":"2176703","id":"PMC_2176703","title":"Critical factors in an enzyme immunoassay (ELISA) for antibodies to mouse thymic virus (MTLV).","date":"1990","source":"Laboratory animals","url":"https://pubmed.ncbi.nlm.nih.gov/2176703","citation_count":4,"is_preprint":false},{"pmid":"27706619","id":"PMC_27706619","title":"Assessing the association between EFEMP1 rs3791679 polymorphism and risk of glioma in a Chinese Han population.","date":"2016","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/27706619","citation_count":4,"is_preprint":false},{"pmid":"40619122","id":"PMC_40619122","title":"The GOLM1-ACLY pathway regulates macrophage-secreted EFEMP1 via H3K27ac modifications to drive tumor progression.","date":"2025","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/40619122","citation_count":3,"is_preprint":false},{"pmid":"39317065","id":"PMC_39317065","title":"Circulating exosomal protein EFEMP1 and SERPINC1 as diagnostic biomarkers for epithelial ovarian cancer.","date":"2024","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39317065","citation_count":3,"is_preprint":false},{"pmid":"26823870","id":"PMC_26823870","title":"EFEMP1 rs3791679 polymorphism was associated with susceptibility to glioma.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26823870","citation_count":3,"is_preprint":false},{"pmid":"39662603","id":"PMC_39662603","title":"Single-cell transcriptomic analysis and luteolin treatment reveal three adipogenic genes, including Aspn, Htra1 and Efemp1.","date":"2024","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/39662603","citation_count":2,"is_preprint":false},{"pmid":"39367272","id":"PMC_39367272","title":"Biallelic and monoallelic variants in EFEMP1 can cause a severe and distinct subtype of heritable connective tissue disorder.","date":"2024","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/39367272","citation_count":2,"is_preprint":false},{"pmid":"2153856","id":"PMC_2153856","title":"Detection of mouse thymic virus (MTLV) antigens in infected thymus by competition immunoassay.","date":"1990","source":"Laboratory animal science","url":"https://pubmed.ncbi.nlm.nih.gov/2153856","citation_count":2,"is_preprint":false},{"pmid":"40640104","id":"PMC_40640104","title":"A review of the role of EFEMP1 in ophthalmic disease.","date":"2025","source":"Ophthalmic genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40640104","citation_count":1,"is_preprint":false},{"pmid":"40316017","id":"PMC_40316017","title":"HIPK4 accelerates cutaneous squamous cell carcinoma progression by phosphorylating TAp63 and inhibiting EFEMP1 expression.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40316017","citation_count":1,"is_preprint":false},{"pmid":"41198612","id":"PMC_41198612","title":"Genetic removal of Nlrp3 protects against age-related and R345W Efemp1-induced basal laminar deposit formation.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41198612","citation_count":1,"is_preprint":false},{"pmid":"39607017","id":"PMC_39607017","title":"EFEMP1 contributes to light-dependent ocular growth in zebrafish.","date":"2024","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/39607017","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52939,"output_tokens":7534,"usd":0.135913,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16771,"output_tokens":6297,"usd":0.12064,"stage2_stop_reason":"end_turn"},"total_usd":0.256553,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"A single non-conservative missense mutation (Arg345Trp) in EFEMP1 was identified as the cause of both Malattia Leventinese and Doyne honeycomb retinal dystrophy, establishing EFEMP1 as the disease gene for these inherited macular degenerations characterized by drusen accumulation beneath the RPE.\",\n      \"method\": \"Positional cloning combined with candidate gene sequencing in affected families; mutation absent in 477 controls and 494 AMD patients\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — positional cloning with candidate gene sequencing, replicated across multiple families, mutation-phenotype co-segregation established\",\n      \"pmids\": [\"10369267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Wild-type EFEMP1 is a secreted protein, whereas the R345W mutant is misfolded, secreted inefficiently, and retained intracellularly; in ML eyes mutant EFEMP1 accumulates within RPE cells and between RPE and drusen, suggesting aberrant intracellular retention drives drusen formation.\",\n      \"method\": \"Cell transfection secretion assays, immunolocalization in human ML and AMD eye sections, Western blot\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (secretion assay, immunohistochemistry in human tissue), consistent findings across ML and AMD specimens\",\n      \"pmids\": [\"12242346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIMP-3 (tissue inhibitor of metalloproteinases-3) was identified as a binding partner of EFEMP1 in the subretinal space; the COOH-terminal end of TIMP-3 mediates the interaction, linking two macular degeneration disease proteins.\",\n      \"method\": \"In vivo subretinal binding partner screen, Co-immunoprecipitation/pulldown, expression overlap analysis in human ML and AMD eye sections\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding confirmed in vivo and by co-localization in human tissue; domain mapping of TIMP-3 C-terminus involvement\",\n      \"pmids\": [\"15123717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The R345W mutation in EFEMP1 is pathogenic: Efemp1-R345W knockin mice develop sub-RPE basal deposits containing Efemp1 and Timp3, and show evidence of complement activation in RPE/Bruch's membrane, recapitulating AMD-like pathology.\",\n      \"method\": \"Efemp1-R345W knockin mouse generation, histopathology, immunofluorescence for Efemp1 and Timp3 in deposits, complement activation assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockin model with histopathological, proteomic, and complement activation readouts; replicated by second concurrent knockin study (PMID:17664227)\",\n      \"pmids\": [\"17666404\", \"17664227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Efemp1 R345W knockin mice develop small isolated sub-RPE deposits as early as 4 months, progressing to continuous sheets with membranous debris, RPE vacuolation, choroidal atrophy, and Bruch's membrane thickening; fibulin-3 accumulates in sub-RPE deposits.\",\n      \"method\": \"Knock-in mouse model histopathology, electron microscopy, immunofluorescence for fibulin-3 in deposits\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knock-in model with detailed longitudinal histopathological characterization, replicated in concurrent knockin study (PMID:17666404)\",\n      \"pmids\": [\"17664227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EFEMP1 binds the EGF receptor (EGFR) competitively relative to EGF, and treatment of pancreatic carcinoma cells with purified EFEMP1 activates EGFR autophosphorylation at Tyr-992 and Tyr-1068, followed by downstream phosphorylation of Akt (Thr-308) and p44/p42 MAPK (Thr-202/Tyr-204); these effects are blocked by the EGFR kinase inhibitor PD 153035.\",\n      \"method\": \"Competitive binding assay (EFEMP1 vs EGF for EGFR), phospho-Western blot for EGFR, Akt, and MAPK phosphorylation sites, kinase inhibitor treatment\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct binding competition assay plus multi-site phosphorylation mapping with site-specific antibodies and pharmacological inhibition in a single study\",\n      \"pmids\": [\"19804359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Secretion deficiency of R345W EFEMP1 is caused, in part, by reduced native disulfide bonding in the sixth EGF-like domain harboring position 345; aromatic residue substitutions (Trp, Tyr, Phe) at position 345 cause significant secretion deficiencies; mutant secretion and proper disulfide formation are enhanced by reduced growth temperature or translational attenuation.\",\n      \"method\": \"Cell-based Gaussia luciferase secretion assay, panel of position-345 mutants, disulfide bond analysis, pharmacological proteostasis manipulation\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis series, biochemical disulfide analysis, and functional rescue experiments in a single rigorous study\",\n      \"pmids\": [\"22031286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Genetic ablation of complement component C3 (but not C5) in Efemp1-R345W knockin mice inhibits formation of sub-RPE basal deposits; proteomic analysis of Bruch's membrane showed basal deposits contain normal ECM components in abnormal amounts and significant increases in complement proteins, demonstrating a critical role for complement (via C3) in basal deposit formation.\",\n      \"method\": \"Double-mutant mouse genetics (Efemp1(R345W/R345W):C3(-/-)), proteomics of Bruch's membrane/choroid, histopathology\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double-mutant mice plus proteomic validation, replicated with C5 study (PMID:34001980) showing C3 but not C5 is critical\",\n      \"pmids\": [\"23943789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HTRA1 serine protease cleaves EFEMP1 as a novel substrate; HTRA1 protein level is increased in high-risk (10q26) RPE cells, accompanied by increased EFEMP1 proteolytic processing.\",\n      \"method\": \"Proteomic comparison of RPE cells with/without high-risk HTRA1 allele, identification of EFEMP1 as HTRA1 cleavage target\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — proteomics-based substrate identification in RPE cells, single lab, no in vitro reconstitution of cleavage reported in abstract\",\n      \"pmids\": [\"29730901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In glioblastoma, EFEMP1 overexpression reduces EGFR protein levels and attenuates AKT signaling, suppresses VEGFA expression and angiogenesis, and inhibits tumor formation when EFEMP1 protein is mixed with cells prior to implantation or injected around established xenografts, indicating it acts in the extracellular compartment; VEGFA re-expression partially restores tumor onset but not overall growth rate.\",\n      \"method\": \"EFEMP1 overexpression/knockdown in glioma cell lines, subcutaneous and intracranial xenograft models, exogenous recombinant protein treatment, ectopic VEGFA rescue experiment, Western blot for EGFR and p-AKT\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal in vitro and in vivo approaches including rescue experiment, knockdown/overexpression, and exogenous protein treatment in a single study\",\n      \"pmids\": [\"21955618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EFEMP1 promotes temozolomide resistance in glioblastoma via γ-secretase-mediated activation of the Notch pathway; silencing EFEMP1 sensitizes cells to TMZ while overexpression causes resistance; γ-secretase inhibitor RO4929097 partially sensitizes cells to TMZ in vitro and in vivo.\",\n      \"method\": \"TMZ-resistant glioblastoma cell line engineering, EFEMP1 siRNA/overexpression, γ-secretase inhibitor treatment, in vitro and in vivo survival assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement via pharmacological inhibition of Notch/γ-secretase with functional rescue, in vitro and in vivo readouts, single lab\",\n      \"pmids\": [\"24495907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EFEMP1 promotes osteosarcoma migration and invasion by directly upregulating MMP-2 expression; EFEMP1 is induced by oncogenic AEG-1 via NF-κB signaling pathway, placing EFEMP1 as a mediator between AEG-1 and MMP-2.\",\n      \"method\": \"EFEMP1 siRNA, plasmid transfection, purified EFEMP1 protein treatment in osteosarcoma cells, NF-κB inhibitor (PDTC), Western blot for MMP-2, invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — pathway placement via pharmacological NF-κB inhibition, siRNA/OE with MMP-2 readout, exogenous protein experiments, single lab\",\n      \"pmids\": [\"25987128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"EFEMP1 inhibits migration of hepatocellular carcinoma cells by suppressing ERK1/2 phosphorylation, leading to decreased MMP-2 and MMP-9 expression; ERK1/2 inhibitor U0126 abrogates the increased migration caused by EFEMP1 siRNA knockdown.\",\n      \"method\": \"EFEMP1 siRNA, purified EFEMP1 protein treatment, ERK1/2 inhibitor U0126, Western blot for ERK1/2, MMP-2, MMP-9, migration assays\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — pharmacological pathway validation via ERK inhibitor rescue plus siRNA and exogenous protein approaches, single lab\",\n      \"pmids\": [\"27108677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In endometrial carcinoma, estrogen/ERα signaling directly binds to an estrogen response element (ERE) in the EFEMP1 promoter and represses EFEMP1 expression; EFEMP1 in turn inhibits epithelial-mesenchymal transition (EMT) by suppressing Wnt/β-catenin signaling targets (Cyclin-D1, c-Myc, Vimentin, Snail).\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, EFEMP1 overexpression/knockdown, Wnt pathway inhibitor XAV93920 and activator LiCl, in vitro EMT marker analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct ChIP and luciferase reporter establish ERα binding to EFEMP1 promoter ERE; functional pathway placement via inhibitor/activator rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27015552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The FBLN3 proximal promoter is contained within 425 bp upstream of exon 1; important regulatory elements include three Sp1-binding sites, a trans-activating Tant motif, and an estrogen response element (ERE) that acts as a trans-repressor; fibulin-3 is expressed in murine and human RPE and in the outer and inner nuclear layers of the retina; estrogen modifies EFEMP1 expression in ARPE-19 cells.\",\n      \"method\": \"Reporter deletion-mutation luciferase transfection assays, in situ hybridization, RT-PCR, estrogen treatment of COS-7 and ARPE-19 cells\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter dissection by reporter assay plus direct localization by in situ hybridization, single lab\",\n      \"pmids\": [\"14578376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Three novel EFEMP1 variants causing juvenile open-angle glaucoma (JOAG) all produce significant intracellular protein aggregation and retention in COS7 cells compared to wild-type; the degree of intracellular retention correlates with disease severity/phenotype across different EFEMP1 mutations.\",\n      \"method\": \"Transient transfection of COS7 cells with EFEMP1 variant constructs, fluorescence microscopy for intracellular accumulation\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cell-based protein retention assay across multiple variants, single lab; supports mechanism but no structural or biochemical follow-up\",\n      \"pmids\": [\"34923728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A loss-of-function cysteine mutation C55R in EFEMP1 forms aberrant extracellular disulfide-linked homodimers, driven by new availability of Cys70 on adjacent monomers; single cysteine mutations near Cys55 (Cys29, Cys42, Cys48, Cys61, Cys70, Cys159, Cys171) also produce similar disulfide-linked dimers; F3 knockout RPE cells show reduced MMP-2 levels and reduced collagen VI ECM filament formation, both partially rescued by wild-type but not C55R F3 re-expression.\",\n      \"method\": \"Dual cysteine mutagenesis, non-reducing SDS-PAGE, F3 knockout RPE cells (CRISPR), Western blot for MMP-2, collagen VI immunostaining, rescue experiments with WT and C55R constructs\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis series with structural inference, KO cell rescue experiment, multiple ECM functional readouts, single lab with orthogonal methods\",\n      \"pmids\": [\"35998264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NLRP3 inflammasome activation is a critical mediator of basal laminar deposit (BLamD) formation in R345W Efemp1 knockin mice; R345W+/+ mice show increased Muller gliosis, subretinal Iba-1+ cells, elevated Nlrp3 immunoreactivity, and transcriptional upregulation of complement C3, Nlrp3, pro-Il1b, and pro-caspase-1 in RPE/choroid; genetic elimination of Nlrp3 or Casp1 significantly reduces BLamD size and coverage.\",\n      \"method\": \"Double-mutant mouse genetics (R345W+/+:Nlrp3-/- and R345W+/+:Casp1-/-), histopathology, immunofluorescence, RT-qPCR for inflammasome components in RPE/choroid\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with double-knockout mice, multiple molecular readouts, single lab with rigorous in vivo design\",\n      \"pmids\": [\"41198612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Wild-type fibulin-3 reduces intracellular actin stress fiber formation and extracellular fibronectin levels in human trabecular meshwork (TM) cells by inhibiting Rho/ROCK signaling; TGFβ1 upregulates fibulin-3 protein in TM cells via Rho/ROCK; overexpression of a stop-codon EFEMP1 mutant (p.X494Q) has opposite effects, increasing IOP and fibronectin in rat eyes.\",\n      \"method\": \"Overexpression of WT and mutant EFEMP1 in human TM cells and rat eyes, actin stress fiber staining, fibronectin Western blot, IOP measurement, Rho/ROCK pathway analysis\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct pathway placement via Rho/ROCK signaling with in vitro and in vivo evidence, single lab, multiple readouts\",\n      \"pmids\": [\"38467175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Fibulin-3 is required for normal elastic fiber organization in the extrahepatic bile duct (EHBD); Efemp1+/- mouse ducts show approximately half the normal elastin fiber density and altered mechanical properties (increased stretch), similar to elastase-treated ducts and neonatal ducts.\",\n      \"method\": \"Histology/staining for elastic fibers in mouse, rat, and human EHBD; pressure myography of Efemp1+/- vs wild-type ducts; elastase treatment comparison\",\n      \"journal\": \"JHEP reports : innovation in hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic haploinsufficiency model with direct mechanical functional readout (pressure myography) and histological quantification, multiple species comparison\",\n      \"pmids\": [\"39717503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In hepatic stellate cells, fibulin-3 (EFEMP1) depletion impairs focal adhesions, FAK phosphorylation, fibronectin network formation, and cell migration, establishing EFEMP1 as a regulator of focal adhesion dynamics and migration in these cells.\",\n      \"method\": \"Gene silencing (EFEMP1 knockdown) in hepatic stellate cells, Western blot for FAK phosphorylation, immunostaining for focal adhesions and fibronectin network, migration assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — loss-of-function with specific cellular phenotypes and molecular readouts, single lab, multiple orthogonal assays\",\n      \"pmids\": [\"40171970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EFEMP1 promotes scleral remodeling in form-deprivation myopia by regulating the PI3K/AKT/MMP2 axis in scleral fibroblasts; AAV-mediated shEFEMP1 injection under Tenon's capsule delays myopia progression and posterior scleral remodeling in guinea pigs, while EFEMP1 overexpression exacerbates myopia and collagen fiber thinning.\",\n      \"method\": \"Lentiviral EFEMP1 overexpression/shRNA in primary scleral fibroblasts, transcriptome sequencing, PI3K inhibitor LY294002, AAV injection in guinea pig form-deprivation myopia model, refraction/axial length measurement, histology\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular basis of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo AAV model plus in vitro pathway inhibitor confirmation of PI3K/AKT/MMP2 axis, single lab, multiple methods\",\n      \"pmids\": [\"38101653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"EFEMP1 binds to STEAP1 and enables Wnt/β-catenin and TGF-β/Smad2/3 signaling to promote EMT in osteosarcoma cells; exogenous EFEMP1 fails to activate these pathways or EMT when STEAP1 is knocked down.\",\n      \"method\": \"EFEMP1 overexpression/knockdown, STEAP1 knockdown, Western blot for Wnt/β-catenin and TGF-β/Smad2/3 pathway markers, EMT marker analysis, rescue experiments\",\n      \"journal\": \"Journal of bone oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — epistasis/rescue experiment places STEAP1 downstream of EFEMP1 with pathway readouts, single lab\",\n      \"pmids\": [\"36388640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FBLN1 (fibulin-1) interacts with EFEMP1 protein and increases its protein stability; FBLN1-mediated suppression of ferroptosis in ectopic endometrial stromal cells requires EFEMP1, as EFEMP1 silencing reverses FBLN1-induced protection from ferroptosis, cell death, and migration.\",\n      \"method\": \"Co-immunoprecipitation (FBLN1-EFEMP1 interaction), EFEMP1 siRNA rescue in FBLN1-overexpressing cells, ferroptosis markers (Fe2+, lipid ROS, MDA, GPX4, GSH), cell viability assays\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP for interaction plus epistasis rescue experiment with multiple ferroptosis readouts, single lab\",\n      \"pmids\": [\"35127942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HIPK4 kinase phosphorylates the transcription factor TAp63 at Ser395, which decreases EFEMP1 expression; this HIPK4-TAp63-EFEMP1 axis promotes cutaneous squamous cell carcinoma progression, and HIPK4 knockdown tumor suppression is reversed by EFEMP1 knockdown.\",\n      \"method\": \"Co-IP and GST-pulldown (HIPK4-TAp63 interaction), ChIP and dual luciferase reporter assay (TAp63 binding to EFEMP1 promoter), phospho-mutagenesis (TAp63 Ser395), HIPK4/EFEMP1 knockdown rescue experiments, mouse tumor models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — kinase-substrate interaction by pulldown, phosphosite mapping, ChIP and reporter for transcriptional regulation, and genetic epistasis rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"40316017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-9 directly targets EFEMP1 in normal fibroblasts (confirmed by luciferase reporter assay); miR-9-induced EFEMP1 silencing recapitulates conversion of normal fibroblasts to cancer-associated fibroblast (CAF)-like cells with increased migration, invasion, and ability to induce cisplatin resistance in breast cancer cells.\",\n      \"method\": \"Luciferase reporter assay for miR-9 targeting of EFEMP1, siRNA knockdown of EFEMP1, migration/invasion assays, co-culture conditioned medium cisplatin resistance assay\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct miRNA target validation by luciferase reporter plus loss-of-function phenotypic recapitulation, single lab\",\n      \"pmids\": [\"32972039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EFEMP1 suppresses hepatocellular carcinoma cell proliferation by promoting Semaphorin 3B (SEMA3B) expression via the Axon guidance pathway; EFEMP1 promotes HCC cell apoptosis mainly through the mitochondrial apoptosis pathway.\",\n      \"method\": \"Lentiviral EFEMP1 overexpression in HCC cells, gene chip expression profiling, GO/pathway analysis, SEMA3B siRNA rescue, apoptosis assays (Annexin V), in vivo xenograft\",\n      \"journal\": \"Cancer medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement relies primarily on gene chip analysis with siRNA rescue, limited mechanistic biochemistry reported in abstract, single lab\",\n      \"pmids\": [\"30972979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Different EFEMP1 missense mutants (p.Met59Leu, p.Arg140Trp, p.Arg345Trp) each increase intracellular protein aggregation but differentially activate ER stress markers (ATF4, GRP78/94, CHOP) and phosphorylation of CREB, AKT, p44/42, and STAT3, demonstrating mutation-dependent signaling consequences.\",\n      \"method\": \"Immunoprecipitation and Western blot for intracellular aggregation, ER stress marker Western blots, phospho-specific antibodies for downstream kinases in HEK293T cells; intravitreal Ad5-EFEMP1 injection in rat eyes for IOP and RGC measurement\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple mutants compared with specific ER stress and signaling readouts in vitro plus in vivo IOP functional validation, single lab\",\n      \"pmids\": [\"38083999\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EFEMP1 (fibulin-3) is a secreted ECM glycoprotein whose wild-type form is efficiently secreted, where it binds TIMP-3 and can engage EGFR to activate MAPK/AKT signaling; disease-causing mutations (notably R345W) cause protein misfolding, impaired disulfide bonding in EGF-like domain 6, reduced secretion, and intracellular retention/aggregation that drives sub-RPE basal deposit formation via complement C3 and NLRP3 inflammasome-dependent mechanisms, while in various cellular contexts EFEMP1 modulates MMP activity, Rho/ROCK-dependent actin cytoskeleton and fibronectin remodeling, Wnt/β-catenin, Notch/γ-secretase, and PI3K/AKT/VEGF signaling to regulate cell migration, invasion, angiogenesis, and apoptosis in a cell-context-dependent manner.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EFEMP1 (fibulin-3) is a secreted extracellular matrix glycoprotein that organizes ECM architecture and modulates multiple signaling pathways governing cell migration, invasion, angiogenesis, and apoptosis in a cell-context-dependent manner [#9, #16, #19]. Wild-type fibulin-3 is efficiently secreted, where it binds the macular-degeneration protein TIMP-3 through TIMP-3's COOH-terminus [#2] and supports ECM functions including MMP-2 production and collagen VI filament assembly [#16] and elastic-fiber organization in tissues such as the extrahepatic bile duct [#19]. In the extracellular compartment EFEMP1 engages EGFR competitively with EGF, triggering EGFR autophosphorylation and downstream AKT and p44/p42 MAPK activation [#5], and across cancer contexts it bidirectionally tunes MMP expression, Wnt/\\u03b2-catenin and TGF-\\u03b2/Smad signaling (in part through binding STEAP1), ERK1/2, PI3K/AKT/VEGF, and Notch/\\u03b3-secretase pathways to either suppress or promote tumor behavior depending on cell type [#9, #11, #13, #22]. EFEMP1 also restrains Rho/ROCK-dependent actin stress-fiber and fibronectin remodeling and regulates focal-adhesion dynamics and FAK phosphorylation [#18, #20]. The single missense mutation Arg345Trp causes the inherited maculopathies Malattia Leventinese and Doyne honeycomb retinal dystrophy [#0]; this and other pathogenic substitutions disrupt native disulfide bonding in EGF-like domain 6, impair secretion, and cause intracellular retention and aggregation [#1, #6, #15, #27]. In R345W knockin mice the misfolded protein and TIMP-3 accumulate in sub-RPE basal deposits, and deposit formation depends critically on complement C3 (but not C5) and on NLRP3 inflammasome/caspase-1 activation [#3, #7, #17]. Distinct loss-of-function cysteine mutations instead drive aberrant extracellular disulfide-linked homodimers with loss of ECM function [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing EFEMP1 as a disease gene answered whether a single locus underlies inherited macular drusen dystrophies, linking the protein to sub-RPE deposit disease.\",\n      \"evidence\": \"Positional cloning and candidate sequencing in families, mutation absent in controls\",\n      \"pmids\": [\"10369267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the cellular mechanism by which R345W causes drusen\", \"Did not address the protein's normal function\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showing that R345W is misfolded and poorly secreted while accumulating in RPE cells reframed the disease as a protein-trafficking defect rather than simple loss of an ECM component.\",\n      \"evidence\": \"Secretion assays in transfected cells and immunolocalization in human ML/AMD eye sections\",\n      \"pmids\": [\"12242346\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural basis of misfolding\", \"Did not show how retained protein triggers deposit formation\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping the FBLN3 promoter and showing retinal expression and estrogen responsiveness established how EFEMP1 transcription is controlled and where the protein is normally made.\",\n      \"evidence\": \"Reporter deletion assays, in situ hybridization, RT-PCR, estrogen treatment of ARPE-19/COS-7 cells\",\n      \"pmids\": [\"14578376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter dissection from a single lab\", \"Functional consequence of estrogen regulation in vivo unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identifying TIMP-3 as a fibulin-3 binding partner connected two macular-degeneration proteins and gave EFEMP1 a defined extracellular interaction in the subretinal space.\",\n      \"evidence\": \"In vivo binding screen, co-IP/pulldown, co-localization, TIMP-3 C-terminus domain mapping\",\n      \"pmids\": [\"15123717\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the interaction not defined\", \"Whether interaction is altered by R345W not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"R345W knockin mice answered whether the mutation is sufficient to cause disease in vivo, recapitulating sub-RPE deposits containing fibulin-3 and TIMP-3 with complement activation.\",\n      \"evidence\": \"Knockin mouse histopathology, EM, immunofluorescence, complement assays (two concurrent studies)\",\n      \"pmids\": [\"17666404\", \"17664227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish causality of complement in deposit formation\", \"Mechanism linking retained protein to deposits unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that EFEMP1 binds EGFR competitively with EGF and activates AKT/MAPK gave the protein a defined extracellular signaling activity beyond a structural ECM role.\",\n      \"evidence\": \"Competitive binding assay, site-specific phospho-Western blots, EGFR kinase inhibitor in pancreatic carcinoma cells\",\n      \"pmids\": [\"19804359\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether EGFR engagement is direct or via co-receptor not resolved\", \"Relevance to retinal disease untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Pinpointing reduced native disulfide bonding in EGF-like domain 6 and rescue by proteostasis manipulation defined the biochemical basis of the secretion defect.\",\n      \"evidence\": \"Luciferase secretion assays, position-345 mutant panel, disulfide analysis, temperature/translation attenuation rescue\",\n      \"pmids\": [\"22031286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve full folded structure of domain 6\", \"Did not link disulfide defect to in vivo deposit formation\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Glioblastoma experiments showed EFEMP1 acts extracellularly to lower EGFR, attenuate AKT, and suppress VEGFA/angiogenesis, establishing a tumor-suppressive, anti-angiogenic role in this context.\",\n      \"evidence\": \"Overexpression/knockdown, xenografts, exogenous protein treatment, VEGFA rescue, Western blot\",\n      \"pmids\": [\"21955618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apparently opposite EGFR effect versus pancreatic carcinoma not reconciled\", \"Receptor-level mechanism of EGFR downregulation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Genetic ablation of C3 (but not C5) in R345W mice answered whether complement is causal, showing C3 is required for basal deposit formation.\",\n      \"evidence\": \"Double-mutant mouse genetics, Bruch's membrane proteomics, histopathology\",\n      \"pmids\": [\"23943789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How retained fibulin-3 triggers complement activation unresolved\", \"Upstream initiator of C3 activation not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking EFEMP1 to \\u03b3-secretase/Notch-mediated temozolomide resistance placed it within a druggable survival pathway in glioblastoma.\",\n      \"evidence\": \"TMZ-resistant cell engineering, siRNA/overexpression, \\u03b3-secretase inhibitor, survival assays in vitro and in vivo\",\n      \"pmids\": [\"24495907\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between EFEMP1 and Notch activation not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining context-dependent MMP regulation showed EFEMP1 can promote (osteosarcoma, MMP-2 via AEG-1/NF-\\u03baB) or suppress (HCC, MMP-2/9 via ERK1/2) invasion depending on cell type, and that ER\\u03b1 directly represses EFEMP1 to relieve Wnt/\\u03b2-catenin-driven EMT in endometrial carcinoma.\",\n      \"evidence\": \"siRNA/overexpression, exogenous protein, pathway inhibitors (PDTC, U0126, XAV93920/LiCl), ChIP and luciferase reporter, EMT/MMP readouts\",\n      \"pmids\": [\"25987128\", \"27108677\", \"27015552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Determinants of context-dependent opposite effects unresolved\", \"Direct receptor mediating each effect not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying EFEMP1 as an HTRA1 cleavage substrate connected the protein to the high-risk 10q26 AMD locus through increased proteolytic processing.\",\n      \"evidence\": \"Proteomic comparison of RPE cells with/without high-risk HTRA1 allele\",\n      \"pmids\": [\"29730901\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro reconstitution of cleavage reported\", \"Functional consequence of cleavage fragments unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"NLRP3/caspase-1 epistasis in R345W mice established inflammasome signaling as a second critical mediator of basal laminar deposit formation alongside complement.\",\n      \"evidence\": \"R345W:Nlrp3-/- and R345W:Casp1-/- double mutants, histopathology, immunofluorescence, RT-qPCR in RPE/choroid\",\n      \"pmids\": [\"41198612\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger of inflammasome activation by retained fibulin-3 unknown\", \"Relationship between C3 and NLRP3 pathways unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that JOAG-causing variants all aggregate intracellularly, with retention correlating with severity, extended the misfolding/retention mechanism beyond retinal disease to glaucoma.\",\n      \"evidence\": \"Transient transfection of variants in COS7 cells, fluorescence microscopy\",\n      \"pmids\": [\"34923728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural or biochemical follow-up\", \"How retention causes raised IOP unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguishing loss-of-function cysteine mutations that form aberrant extracellular disulfide-linked homodimers, plus KO-cell rescue, defined fibulin-3's normal ECM role in MMP-2 and collagen VI assembly and a distinct dimerization mechanism of dysfunction.\",\n      \"evidence\": \"Dual cysteine mutagenesis, non-reducing SDS-PAGE, CRISPR KO RPE cells, MMP-2/collagen VI readouts, WT vs C55R rescue\",\n      \"pmids\": [\"35998264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo consequence of homodimerization untested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying STEAP1 as an EFEMP1 binding partner required for Wnt/\\u03b2-catenin and TGF-\\u03b2/Smad-driven EMT provided a receptor-level handle on EFEMP1 pro-tumor signaling in osteosarcoma.\",\n      \"evidence\": \"Overexpression/knockdown, STEAP1 knockdown epistasis, pathway/EMT Western blots, rescue\",\n      \"pmids\": [\"36388640\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct EFEMP1-STEAP1 binding not biochemically mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing FBLN1 binds and stabilizes EFEMP1 to suppress ferroptosis in endometrial stromal cells added a protein-stability partnership and a redox-survival role.\",\n      \"evidence\": \"Co-IP, EFEMP1 siRNA rescue in FBLN1-overexpressing cells, ferroptosis markers, viability assays\",\n      \"pmids\": [\"35127942\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of stabilization unresolved\", \"Single lab, reciprocal validation limited\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Comparing multiple missense mutants showed they share intracellular aggregation but differentially activate ER-stress and downstream kinase signaling, indicating mutation-specific gain-of-function consequences.\",\n      \"evidence\": \"IP/Western for aggregation, ER-stress markers, phospho-antibodies in HEK293T; intravitreal Ad5-EFEMP1 in rat eyes\",\n      \"pmids\": [\"38083999\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between specific ER-stress signature and disease phenotype unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrating EFEMP1 regulation of scleral remodeling via PI3K/AKT/MMP2, with AAV knockdown delaying myopia, broadened its role to ocular ECM remodeling beyond the RPE.\",\n      \"evidence\": \"Lentiviral OE/shRNA in scleral fibroblasts, transcriptomics, PI3K inhibitor, AAV in guinea pig myopia model, histology\",\n      \"pmids\": [\"38101653\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating EFEMP1 signaling in sclera not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defining fibulin-3 control of Rho/ROCK-dependent stress fibers and fibronectin in trabecular meshwork, and its requirement for elastic-fiber organization in the bile duct, established core cytoskeletal/ECM-remodeling functions of the wild-type protein.\",\n      \"evidence\": \"WT/mutant OE in TM cells and rat eyes with IOP/fibronectin readouts; Efemp1+/- mouse bile-duct histology and pressure myography\",\n      \"pmids\": [\"38467175\", \"39717503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between fibulin-3 and Rho/ROCK not defined\", \"Whether bile-duct elastin role applies to other tissues unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Loss-of-function in hepatic stellate cells and transcriptional control by the HIPK4-TAp63 and miR-9 axes refined how EFEMP1 abundance is set and how it controls focal-adhesion dynamics, migration, and tumor progression.\",\n      \"evidence\": \"EFEMP1 knockdown with FAK/focal-adhesion/fibronectin readouts (stellate cells); HIPK4-TAp63 pulldown, ChIP/reporter, phospho-mutagenesis, knockdown rescue and tumor models; miR-9 luciferase target validation\",\n      \"pmids\": [\"40171970\", \"40316017\", \"32972039\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct downstream effector of focal-adhesion regulation unresolved\", \"Integration of the multiple upstream regulators in vivo unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How intracellular retention of misfolded EFEMP1 mechanistically triggers complement C3 and NLRP3 inflammasome activation in the RPE, and what reconciles its opposite signaling outcomes across cell types, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined molecular link between ER retention and complement/inflammasome activation\", \"No unifying receptor model explaining context-dependent pro- vs anti-tumor effects\", \"No high-resolution structure of EGF-like domain 6 explaining disulfide-dependent misfolding\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 9, 18]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2, 9]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 6, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 18, 22]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 3, 7, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TIMP3\", \"EGFR\", \"HTRA1\", \"STEAP1\", \"FBLN1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}